Answers are grounded in this paper and cite their sources.
Sarcopenia is a heterogeneous skeletal-muscle disease in which mitochondrial bioenergetic decline is recurrent. In a discovery transcriptome (GSE226151) screened by differential expression and monotonic trend within a candidate space annotated with database-derived nicotine targets, five algorithms converged on one gene, CKMT2. Across four human vastus lateralis cohorts (268 donors; three independent of discovery), CKMT2 was lower in cases (pooled Hedges’ g = −0.60, p = 0.006), and between-cohort heterogeneity was explained entirely by case definition: the deficit was large and consistent in sarcopenia-defined cohorts ( g = −1.01) but small and nonsignificant in frailty-defined cohorts ( g = −0.27; between-subgroup p = 0.008). Its discrimination did not survive adjustment for mitochondrial content and fiber-type composition (area under the curve [AUC]: 0.77–0.49), its effect size lay at the median of 76 oxidative-phosphorylation subunits, and it was unchanged by 6 months of resistance training in 72 donors with paired biopsies. At protein-level CKMT2 was 31% lower in sarcopenic than healthy older muscle, while cytosolic CKM and CKB were unchanged. Single-nucleus analysis linked lower CKMT2 to reduced oxidative phosphorylation and attenuated contractile programs. CKMT2 marks a coordinated mitochondrial and oxidative-fiber program rather than an independent biomarker. All analyses are computational; no experimental validation was performed.
No takes yet. Share an insight, caveat, or question.
戚力升 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: